Antioxidants inhibit neuronal toxicity in Parkinson's disease-linked LRRK2

Annals of Clinical and Translational Neurology

Volumn 3, Issue 4, 2016, Pages 288-294

  Angeles, Dario C ^a,b   Ho, Patrick ^c   Dymock, Brian W ^b   Lim, Kah Leong ^b,c,d   Zhou, Zhi Dong ^a   Tan, Eng King ^a,c,d  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ESCULETIN; LEUCINE RICH REPEAT KINASE 2; PICEATANNOL; STAUROSPORINE; THYMOQUINONE;

ARTICLE; ASSAY; CELL VIABILITY; CONTROLLED STUDY; DROSOPHILA; ENZYME INHIBITION; HUMAN; PARKINSON DISEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RADIOMETRIC KINASE ASSAY; SCREENING; VALIDATION PROCESS;

EID: 84973350290     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.282     Document Type: Article

References (20)

1. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009;373:2055-2066.
2. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009;8:1150-1157.
3. Tarazi FI, Sahli ZT, Wolny M, Mousa SA. Emerging therapies for Parkinson's disease: from bench to bedside. Pharmacol Ther 2014;144:123-133.
4. Tan EK, Skipper LM. Pathogenic mutations in Parkinson disease. Hum Mutat 2007;28:641-653.
5. Chan SL, Angeles DC, Tan EK. Targeting leucine-rich repeat kinase 2 in Parkinson's disease. Expert Opin Ther Targets 2013;17:1471-1482.
6. Piccoli G, Condliffe SB, Bauer M, et al. LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J Neurosci 2011;31:2225-2237.
7. MacLeod D, Dowman J, Hammond R, et al. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006;52:587-593.
8. Stafa K, Trancikova A, Webber PJ, et al. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet 2012;8:e1002526.
9. Chan SL, Chua LL, Angeles DC, Tan EK. MAP1B rescues LRRK2 mutant-mediated cytotoxicity. Mol Brain 2014;7:29.
10. Kramer T, Lo Monte F, Göring S, et al. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models. ACS Chem Neurosci 2012;3:151-160.
11. Angeles DC, Gan B-H, Onstead L, et al. Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death. Hum Mutat 2011;32:1390-1397.
12. Jaleel M, Nichols RJ, Deak M, et al. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 2007;405:307-317.
13. Angeles DC, Ho P, Chua LL, et al. Thiol peroxidases ameliorate LRRK2 mutant-induced mitochondrial and dopaminergic neuronal degeneration in Drosophila. Hum Mol Genet 2014;23:3157-3165.
14. Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson's disease. J Parkinsons Dis 2013;3:461-491.
15. Schapira AH, Patel S. Targeting mitochondria for neuroprotection in Parkinson disease. JAMA Neurol 2014;71:537-538.
16. Geahlen RL, McLaughlin JL. Piceatannol (3, 4, 3′, 5′-tetrahydroxy-trans-stillbene) is a naturally occurring protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun 1989;165:241-245.
17. Kidd PM. Bioavailability and activity of phytosome complexes from botanical polyphenols; the silymarin, curcumin, green tea, and grape seed extracts. Altern Med Rev 2009;14:226-246.
18. Bhullar KS, Rupasinghe HP. Polyphenols: multipotent therapeutic agents in neurodegenerative diseases. Oxid Med Cell Longev 2013;2013:891748.
19. Radad K, Moldzio R, Taha M, Rausch WD. Thymoquinone protects dopaminergic neurons against MPP+ and rotenone. Phytother Res 2009;23:696-700.
20. Subramaniam SR, Ellis EM. Neuroprotective effects of umbelliferone and esculetin in a mouse model of Parkinson's disease. J Neurosci Res 2013;91:453-461.